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Efﬁcacy of interferon-based antiviral therapy on the risk
of hepatocellular carcinoma of patients with chronic hepatitis
C: Further evidence in decompensation cirrhosis
To the Editor:
We read with great interest the paper by Eiichi Ogawa and col-
leagues [1], accepted for publication in the Journal of Hepatology.
The authors performed a large-scale, multicenter, prospective
study and presented important data regarding the observation
that sustained virological response (SVR) and transient virolog-
ical response (TVR: deﬁned as relapse or breakthrough) were
associated with a lower risk of development of hepatocellular
carcinoma (HCC) in patients with chronic hepatitis C, with or
without cirrhosis, when compared with non-virological
response (NVR). However, cirrhotic patients with advanced dis-
ease, namely decompensated cirrhosis, have been excluded from
their study. No study to date has provided evidence that virus
suppression and elimination after interferon (IFN)-based antivi-
ral therapy reduce the risk of HCC in this difﬁcult-to-treat pop-
ulation. We performed a prospective pilot trial to investigate the
safety and efﬁcacy of pegylated/standard IFN-a combined with
ribavirin for decompensated cirrhosis patients with HCV
infection.
From January 2008 to January 2011, 50 consecutive, IFN-naïve
HCV decompensated cirrhotic patients were treated with PegIFN-
a-2b at 1.0–1.5 lg/kg/week or standard IFN-a-2b, 3MU, thrice
weekly, plus ribavirin at 800–1000 mg/day for 48 weeks, with a
low accelerating dosage regimen. The diagnosis of decompen-
sated liver cirrhosis was made when a patient had experienced
one or more of the following clinical symptoms: ascites, variceal
bleeding, spontaneous bacterial peritonitis (SBP), and encepha-
lopathy, which referred to Iacobellis’ and our previous studies
[2,3]. Patients with HCC, chronic renal failure, unstable cardiovas-
cular disease, severe chronic obstructive lung disease, co-infec-
tion with immunodeﬁciency or hepatitis B viruses, current
alcohol abuse, platelets <35,000/ll, neutrophils <1000/ll, hae-
moglobin <100 g/L, or Child-Pugh class C were excluded [2,3].
Patients were routinely monitored for SVR, TVR, and NVR accord-
ing to the accepted guidelines and Ogawa’s study [1,4]. The pri-
mary end point of our study was the assessment of HCC
development after treatment; the length of the follow-up period
was calculated from the end of the antiviral therapy to the diag-
nosis of HCC or the last follow-up visit. The secondary end point
was to investigate further events of decompensation after
treatment.
The baseline characteristics and clinical prognosis of the 50
studied patients as classiﬁed by treatment outcome, are shown
in Table 1. There was no HCC development during antiviral treat-
ment. Of all patients, 9 (18%) required premature treatment with-
drawal because of adverse effects and/or poor virological
response. Of the studied patients, 21 achieved SVR (42.0%), 15
were TVR (30.0%), and 14 (28.0%) were NVR. Median follow-up
off-therapy was 29 (range 8–45) months, seven (14%) patients
developed HCC, including 2/21 with SVRs (9.5%), 1/15 with TVRs
(6.7%) and 4 of 14 with NVRs (28.6%), respectively. During the fol-
low-up period, 4/21 patients with SVRs (19.0%), 5/15 (33.3%) with
TVRs and 13 out of 14 without virological response (92.9%) expe-
rienced further events of decompensation (p <0.001).
In patients with HCV compensated cirrhosis, a signiﬁcant
reduction in the annual incidence of HCC has been reported after
SVR [5,6]; andOgawa and colleagues found that compensation cir-
rhotic patients with TVR also have a lower incidence rate of HCC
compared with patients with NVR. For decompensation cirrhotic
patients in our study, althougha lownumberof patients developed
HCC and the observation period was short, the Kaplan–Meier
curves for the end point of HCC showed a noticeable separation
of both patientswith SVR and TVR from thosewithNVR, at approx-
imately16 monthsofpost-treatment follow-up (overall:p = 0.048,
SVR vs. TVR: p = 0.887, SVR vs. NVR: p = 0.045, and TVR vs. NVR:
p = 0.089byLog-rank test) (SupplementaryFig. 1). It is inconsistent
with the results of the study showing that HCC developed at com-
parable rates in decompensation cirrhotic patients with and with-
out SVR during a 5-year follow-up, upon completion of the
combination therapy [7]. One possible explanation for the discrep-
ant results may be that the efﬁcacy of TVR on the risk of HCC was
included in no SVR group, in their study [7]. An intriguing ﬁnding
from our study is that 72% (36/50) of decompensation cirrhotic
patients, compared with 68% (102/150) of compensation cirrhotic
patients in Ogawa and colleagues’ study, had an undetectable HCV
RNA at the end of treatment. Asians have a signiﬁcantly higher
probability of viral response to IFN-based antiviral therapy has
been attributed to genetic variants in the interleukin (IL)-28B gene
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[8–10].None of our patients underwent IL28B genotyping analysis;
whether IL28B genotyping contributed to the high viral response in
our studyneeds further clariﬁcation.However, the fact is thatmore
cirrhotic patientsmaybeneﬁt fromantiviral treatment in East Asia.
In summary, our data indicate that complete viral suppres-
sion during antiviral treatment may play an important role in
preventing the development of HCC in patients with HCV
decompensated cirrhosis, and add further evidence for virus
suppression and elimination after IFN-based antiviral therapy
reduce the risk of HCC in patients with chronic hepatitis C by
Ogawa et al. However, results from large and well-designed
long-term studies are awaited. Since cirrhosis is an independent
risk factor for HCC and the considerable risk of developing HCC
remains even after HCV eradication, a vigilant monitoring of
HCC development in patients with HCV-related compensated
and decompensated cirrhosis should be mandatory, irrespective
of SVR.
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Table 1. Pretreatment characteristics and clinical prognosis of 50 patients with decompensated cirrhosis classiﬁed by the treatment outcome.
Characteristic SVR
n = 21
TVR
n = 15
NVR
n = 14
p value*
Age (yr) 57 (51-64) 55 (48-61) 58 (50-65) 0.695
Male, n (%) 10 (47.6) 6 (40) 5 (35.7) 0.770
Serum total bilirubin (μmol/L) 25.3 (18.7-33) 23.0 (14.7-30.7) 22.8 (17.0-29.7) 0.609
Alanine aminotransferase (IU/L) 73 (67-86) 63 (44-75) 60 (47-72) 0.136
Serum albumin (g/L) 35.6 (33.6-37.7) 36.2 (34.3-37.7) 35.7 (33.7-38.1) 0.765
PTA (%) 72 (66-81) 72 (67-78) 68 (61-77) 0.312
Platelet count (×103/μl) 74 (58-85) 65 (47-81) 59 (43-73) 0.043
Neutrocyte count (×103/μl) 1.6 (1.4-1.8) 1.6 (1.3-1.8) 1.4 (1.1-1.8) 0.070
Hemoglobin (g/L) 119 (108-131) 120 (112-127) 122 (114-132) 0.760
α-fetoprotein (ng/ml) 11.8 (7.8-15.9) 12.1 (8.2-16.5) 15.1 (13.3-18.4) 0.070
HCV genotype (1/2), n (%) 11/10 (52.4/47.6) 11/4 (73.3/26.7) 13/1 (92.9/7.1) 0.036
Experienced further decompensation, n (%) 4 (19.0) 5 (33.3) 13 (92.9) <0.001
Data are expressed as number (%) or mean and interquartile range.
⁄Statistical analysis was performed using the Chi-square, Fisher’s exact test or one-way ANOVA following conﬁrmation of normal distribution of data; the comparison is
among the three groups.
SVR, sustained virological response; TVR, transient virological response; NVR, non-virological response; PTA, prothrombin time activity; HCV, hepatitis C virus.
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Regular coffee: A magic bullet or a naked gun? Regular coffee but
not espresso drinking is protective against ﬁbrosis in NAFLD
To the Editor:
We read with interest the article by Anty et al. [1] reporting that
consumption of regular coffee but not of espresso is an indepen-
dent protective factor for liver ﬁbrosis, in severely obese Euro-
pean patients. Effects of coffee and caffeine on liver disease,
including NAFLD, cirrhosis and HCC, have been reported over sev-
eral years, with different methodological approaches and non-
univocal results [2–4]. We appreciate the great effort that the
authors have put, working with an extremely selected popula-
tion, and using very careful tools for the assessment of steatosis
and ﬁbrosis. Nonetheless, it appears useful to challenge the effec-
tive reliability of the methodology they have chosen for reaching
their results and conclusion. The enthusiasm of the conclusion is
perhaps not adequately supported by consistent data and is mis-
leading for readers: ‘‘Consumption of regular ﬁltrated coffee but not
espresso was independently associated with a lower level of ﬁbrosis
in morbidly obese European patients. The ﬁnding that some com-
pounds in coffee can protect from liver ﬁbrosis is of potential phar-
macological interest. As sugar could decrease the beneﬁcial effect
of coffee, coffee consumption, particularly regular coffee, could be
encouraged but without sugar addition!’’ [1]. The authors [1]
describe coffee both as a nutrient and as a blend of drugs, and
also as different recipes. Why not as a high quality beverage?
Looking at the statements of the conclusion, some details are
not available: which espresso? Which pharmacological effect?
From where does the sugar appear and is there any information
on sugars in this study? Moreover, the predictive models used
are not clearly described. Actually, it seems that only four of
the six statistically different measures in the two groups are used
(AST, caffeine from regular coffee, HOMA-IR and NASH) skipping
ALT and quantity of regular coffee consumed (ml/wk). It is rea-
sonable, in our view, that challenging and showing (if the current
table refers to a stepwise regression) a more extended model
could be possible and useful. In the data analysis, it is not clear
if the overlap of use of different coffee beverages has any effect:
the calculation of the overall content of caffeine appears very
conjectural due to the obvious diversity of different coffee reci-
pes. Essentially, 38 subjects (19.5%) drank only regular coffee,
76 (39%) only espresso: perhaps a plain comparison of these
two ‘‘almost-pure’’ groups, as these are, could help. Information
on regular coffee and caffeine intake relies entirely on self-report-
ing of the subjects and, much more important, depends on the
quantity accounted for in this way. On this basis, the conclusion
that different coffee recipes and preparations really have a
homogenous content of caffeine is quite difﬁcult to conﬁrm or
accept. Even the deﬁnition of ‘‘espresso’’ cup adopted by Anty
et al. [1] is very far from what the word really represents [5]:
the current quantity of a cup of espresso [5] is almost 10–15%
of the quantity stated by the authors in the table available as Sup-
plementary material of the article [1]. There is also a different
perspective: it is possible, if not likely, that the nutritional behav-
ior of obese people using regular coffee – any quantity – is differ-
ent from the nutritional and lifestyle behavior (including physical
exercise) of obese people drinking espresso coffee. Unfortunately,
in this study, we do not have any information on the nutritional
proﬁle of this population and of the two main subgroups. No
information is available on their physical exercise habits, socio-
economical status and other factors that could affect food intake
and obesity. Last but not least, no deﬁnition of ‘‘malnutrition’’ and
of related markers is considered: it should be considered and
could be a useful issue in dealing with obesity, steatosis and
ﬁbrosis in liver disease. Overall, several major confounders are
not sufﬁciently taken into account in this study, as it is currently
presented: interpretations should have been more carefully
reviewed by the authors and, particularly, some reappraisal of
correlations introduced. The latter as presented and interpreted,
may be confusing if not misleading. The article is still lacking reli-
able nutritional information in the prevention or treatment, if
any, of ﬁbrosis and NAFLD, and we need consistent evidence
and less conjecture.
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